Titre:	Anti‑EpCAM antibodies for detection of metastatic carcinoma in effusions and peritoneal wash
Auteur(s):	Carneiro, Fabiana Pirani Muniz‑Junqueira, Maria Imaculada Carneiro, Marcos de Vasconcelos Oliveira, Ísis de Araújo Soares, Aluízio Carlos Haar, Nathália de Vargas Takano, Gustavo Henrique Soares Vianna, Leonora Maciel de Sousa Caldas, Guilherme de Carvalho Vieira, Danillo Leal Marinho Frutuoso, Lígia Lins Brito, Larissa Matos Rodrigues Siqueira, Rafael Vieira Martins de Parente, Amanda Moreira Castro, Tercia Maria Mendes Lousa de Peres, Isabela Mendes, Lianna Martha Soares Borges, Tatiana Karla dos Santos Ferreira, Vânia Moraes Motoyama, Andrea Barretto
Assunto::	Câncer Anticorpos Imunocitoquímica Derrame
Date de publication:	2019
Editeur:	Spandidos Publications
Référence bibliographique:	CARNEIRO, Fabiana Pirani et al. Anti‑EpCAM antibodies for detection of metastatic carcinoma in effusions and peritoneal wash. Oncology y Letters, v. 18, p. 2019-2024, 2019. DOI: 10.3892/ol.2019.10468. Disponível em: https://www.spandidos-publications.com/10.3892/ol.2019.10468/abstract. Acesso em: 02 dez. 2019.
Abstract:	Epithelial cell adhesion molecule (EpCAM) has been used as diagnostic/prognostic marker and therapeutic target. The aim of the present study was to compare immunoreactivity of antibodies against distinct epitopes in the ectodomain of EpCAM for detection of carcinoma from different primary sites and of different histological types in effusions and peritoneal wash. Two antibodies against epitopes in the EGF‑like domain I (clones Moc‑31 and Ber‑EP4) and one antibody against the epitope in the cysteine‑poor region (158210) of EpCAM were used (all commercially available). Independently of the clone used, EpCAM overexpression was observed in almost all samples when all the adenocarcinoma samples were analyzed together. By using Moc‑31, EpCAM overexpression was observed in all samples of adenocarcinoma. Absence of EpCAM overexpression was observed in a few adenocarcinoma samples at some sites of tumor origin, including ovary, breast and stomach, when Ber‑EP4 and 158210 were used. Regarding carcinomas aside from adenocarcinomas, histological types, such as squamous cell, urothelial and small cell carcinoma showed different degrees of EpCAM expression according to the antibody used. In squamous cell carcinoma, overexpression was observed only with the clone 158210. It was concluded that, overall, most samples of metastatic carcinoma from effusions showed overexpression of EpCAM. However, there are significant variations in its detection according to the primary site, histological type of the carcinoma and depending on the antibody used. Thus, the use of more than one type of anti‑EpCAM antibody would increase the chance of its detection in metastatic carcinoma effusion.
metadata.dc.description.unidade:	Faculdade de Medicina (FM)
DOI:	10.3892/ol.2019.10468
metadata.dc.relation.publisherversion:	https://www.spandidos-publications.com/10.3892/ol.2019.10468/abstract
Collection(s) :	Artigos publicados em periódicos e afins

Tous les documents dans DSpace sont protégés par copyright, avec tous droits réservés.